Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab
NCT05889442Completed
- Sponsor
- Dansk Hovedpinecenter
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in migraine without aura comparing Levcromakalim with Placebo (2 arms). Primary endpoint: Incidence of migraine attack at 12 hours. Started Mar 2023; status: completed.
02
Drugs
levcromakalim
03
Conditions
migraine without aura
Beyond the preview
Go deeper on NCT05889442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889442.